给这些心衰患者置入ICD,涉嫌过度医疗!

2016-09-06 卢芳 医师报

丹麦哥本哈根大学医院 Lars Kober 教授报告的DANISH 研 究 显 示, 对于非缺血性收缩性心衰患者,置入埋藏式心脏复律除颤器(ICD)虽然降低了猝死风险,但并不能改善生存率。该研究论文同期发表于《新英格兰医学杂志》。“当前美国心脏学会发布的指南将左心室收缩功能降低的心衰患者预防性 置 入 ICD 列 为 Ⅰ A 类推荐,但并未区分病因是缺血还是非缺血。而欧洲指南 则 将 非 缺 血

丹麦哥本哈根大学医院 Lars Kober 教授报告的DANISH 研 究 显 示, 对于非缺血性收缩性心衰患者,置入埋藏式心脏复律除颤器(ICD)虽然降低了猝死风险,但并不能改善生存率。该研究论文同期发表于《新英格兰医学杂志》。

“当前美国心脏学会发布的指南将左心室收缩功能降低的心衰患者预防性 置 入 ICD 列 为 Ⅰ A 类推荐,但并未区分病因是缺血还是非缺血。而欧洲指南 则 将 非 缺 血 性 心 衰置 入 ICD 列 为 Ⅰ B 类推荐。总而言之,一直以来对于非缺血性病因所致心衰是否应该置入 ICD 证据支持较为薄弱。我们的研究填补了空白,并提示对于非缺血性收缩性心衰患者不应一概而论常规置入ICD。”Kober 说。

DANISH 研 究 是 一项随机对照多中心研究,共 纳 入 1116 例 慢 性 非 缺血性收缩性心衰患者,其中有 556 例患者随机置入ICD, 另 外560 例 患 者 则接受常规指南所推荐的药物治疗。两组均有 58% 的患者接受了 CRT 治疗。

在随访 67.6 个月后,置入 ICD 患者组和常规治疗组发生全因死亡率相似(21.6% 与23.4%); 但ICD 组猝死发生率显著降低(4.3% 与 8.2%)。

进一步分析发现,研究 结 果 与 是 否 接 受CRT治疗无关,而年龄却在其中扮有重要角色。“< 68岁的患者在接受 ICD 治疗后全因死亡率显著降低,这提示,或许年轻患者置入 ICD 可 获益。”Kober指出。

研究还显示,置入设备引起的感染在 ICD 组有额外风险(5.1% 与 0.8%)。此外,ICD 组还发生 5.9%的不恰当放电。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1860467, encodeId=a3a8186046ebd, content=<a href='/topic/show?id=d064933e0b' target=_blank style='color:#2F92EE;'>#ICD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9337, encryptionId=d064933e0b, topicName=ICD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87f580, createdName=yilong5287542, createdTime=Sun Jun 11 04:48:00 CST 2017, time=2017-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373317, encodeId=c14213e3317d5, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Thu Sep 08 00:48:00 CST 2016, time=2016-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1518782, encodeId=f7cf1518e823d, content=<a href='/topic/show?id=dc85939999c' target=_blank style='color:#2F92EE;'>#过度医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93999, encryptionId=dc85939999c, topicName=过度医疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7ca11178291, createdName=lvliquan, createdTime=Thu Sep 08 00:48:00 CST 2016, time=2016-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112234, encodeId=6c181122343b, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 06 13:48:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112235, encodeId=99941122356a, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 06 13:48:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112236, encodeId=f6ae11223624, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 06 13:48:00 CST 2016, time=2016-09-06, status=1, ipAttribution=)]
    2017-06-11 yilong5287542
  2. [GetPortalCommentsPageByObjectIdResponse(id=1860467, encodeId=a3a8186046ebd, content=<a href='/topic/show?id=d064933e0b' target=_blank style='color:#2F92EE;'>#ICD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9337, encryptionId=d064933e0b, topicName=ICD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87f580, createdName=yilong5287542, createdTime=Sun Jun 11 04:48:00 CST 2017, time=2017-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373317, encodeId=c14213e3317d5, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Thu Sep 08 00:48:00 CST 2016, time=2016-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1518782, encodeId=f7cf1518e823d, content=<a href='/topic/show?id=dc85939999c' target=_blank style='color:#2F92EE;'>#过度医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93999, encryptionId=dc85939999c, topicName=过度医疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7ca11178291, createdName=lvliquan, createdTime=Thu Sep 08 00:48:00 CST 2016, time=2016-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112234, encodeId=6c181122343b, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 06 13:48:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112235, encodeId=99941122356a, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 06 13:48:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112236, encodeId=f6ae11223624, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 06 13:48:00 CST 2016, time=2016-09-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1860467, encodeId=a3a8186046ebd, content=<a href='/topic/show?id=d064933e0b' target=_blank style='color:#2F92EE;'>#ICD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9337, encryptionId=d064933e0b, topicName=ICD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87f580, createdName=yilong5287542, createdTime=Sun Jun 11 04:48:00 CST 2017, time=2017-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373317, encodeId=c14213e3317d5, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Thu Sep 08 00:48:00 CST 2016, time=2016-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1518782, encodeId=f7cf1518e823d, content=<a href='/topic/show?id=dc85939999c' target=_blank style='color:#2F92EE;'>#过度医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93999, encryptionId=dc85939999c, topicName=过度医疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7ca11178291, createdName=lvliquan, createdTime=Thu Sep 08 00:48:00 CST 2016, time=2016-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112234, encodeId=6c181122343b, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 06 13:48:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112235, encodeId=99941122356a, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 06 13:48:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112236, encodeId=f6ae11223624, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 06 13:48:00 CST 2016, time=2016-09-06, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1860467, encodeId=a3a8186046ebd, content=<a href='/topic/show?id=d064933e0b' target=_blank style='color:#2F92EE;'>#ICD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9337, encryptionId=d064933e0b, topicName=ICD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87f580, createdName=yilong5287542, createdTime=Sun Jun 11 04:48:00 CST 2017, time=2017-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373317, encodeId=c14213e3317d5, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Thu Sep 08 00:48:00 CST 2016, time=2016-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1518782, encodeId=f7cf1518e823d, content=<a href='/topic/show?id=dc85939999c' target=_blank style='color:#2F92EE;'>#过度医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93999, encryptionId=dc85939999c, topicName=过度医疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7ca11178291, createdName=lvliquan, createdTime=Thu Sep 08 00:48:00 CST 2016, time=2016-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112234, encodeId=6c181122343b, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 06 13:48:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112235, encodeId=99941122356a, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 06 13:48:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112236, encodeId=f6ae11223624, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 06 13:48:00 CST 2016, time=2016-09-06, status=1, ipAttribution=)]
    2016-09-06 doctorJiangchao

    继续关注

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1860467, encodeId=a3a8186046ebd, content=<a href='/topic/show?id=d064933e0b' target=_blank style='color:#2F92EE;'>#ICD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9337, encryptionId=d064933e0b, topicName=ICD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87f580, createdName=yilong5287542, createdTime=Sun Jun 11 04:48:00 CST 2017, time=2017-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373317, encodeId=c14213e3317d5, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Thu Sep 08 00:48:00 CST 2016, time=2016-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1518782, encodeId=f7cf1518e823d, content=<a href='/topic/show?id=dc85939999c' target=_blank style='color:#2F92EE;'>#过度医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93999, encryptionId=dc85939999c, topicName=过度医疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7ca11178291, createdName=lvliquan, createdTime=Thu Sep 08 00:48:00 CST 2016, time=2016-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112234, encodeId=6c181122343b, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 06 13:48:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112235, encodeId=99941122356a, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 06 13:48:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112236, encodeId=f6ae11223624, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 06 13:48:00 CST 2016, time=2016-09-06, status=1, ipAttribution=)]
    2016-09-06 doctorJiangchao

    继续关注

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1860467, encodeId=a3a8186046ebd, content=<a href='/topic/show?id=d064933e0b' target=_blank style='color:#2F92EE;'>#ICD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9337, encryptionId=d064933e0b, topicName=ICD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87f580, createdName=yilong5287542, createdTime=Sun Jun 11 04:48:00 CST 2017, time=2017-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373317, encodeId=c14213e3317d5, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Thu Sep 08 00:48:00 CST 2016, time=2016-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1518782, encodeId=f7cf1518e823d, content=<a href='/topic/show?id=dc85939999c' target=_blank style='color:#2F92EE;'>#过度医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93999, encryptionId=dc85939999c, topicName=过度医疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7ca11178291, createdName=lvliquan, createdTime=Thu Sep 08 00:48:00 CST 2016, time=2016-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112234, encodeId=6c181122343b, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 06 13:48:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112235, encodeId=99941122356a, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 06 13:48:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112236, encodeId=f6ae11223624, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 06 13:48:00 CST 2016, time=2016-09-06, status=1, ipAttribution=)]
    2016-09-06 doctorJiangchao

    继续关注

    0

相关资讯

有时改善心梗、有时改善心衰、总是降低血糖

【新闻事件】:这一周的JAMA发表了一篇诺和诺德GLP-1激动剂利拉鲁肽注射液在心衰患者的临床试验结果。这个300人的随机、对照、双盲二期临床试验比较1.8毫克利拉鲁肽和安慰剂对左心室射血减弱急性心衰患者病情的帮助,一级终点是住院后生存时间、再住院间隔、和6个月氮末端B型脑钠肽前体变化的复合终点。结果无论患者是否有糖尿病,利拉鲁肽未能显示任何疗效(包括二级终点的生活质量、6分钟走)。对于严重心衰的

全新的研究显示,低盐饮食损伤心脏,增加慢性心衰的死亡率

最近,美国拉什大学芝加哥医学中心对低盐饮食进行了研究,研究观察了800多位心衰的患者,调查他(她)们的健康状况和盐的摄入情况,结果令人震惊,低盐饮食人群的死亡、或住院的发生率比不限制盐饮食的人群高出了85%。研究者最后得出结论,低盐饮食可能对身体有害1,2。         与主流的建议正好相反,近年来,越来越多的研究

CFDA再次修订警告:这种降糖药可增加心衰风险!

8月12日,国家食品药品监督管理总局(CFDA)官网发布了《关于修订罗格列酮及其复方制剂说明书的公告》,对降糖药罗格列酮及其复方制剂说明书的【警示语】、【适应症】、【不良反应】、【禁忌】、【注意事项】等项目进行了再一次的修订——其实,这已是CFDA第三次发布有关罗格列酮的公告了——第一次是在2010年10月15日,CFDA在组织相关专家对罗格列酮及其复方制剂在我国临床使用的安全性进行了评估后,

Heart:心衰患者射血分数、QRS间期的种族差异性研究

根据发表在Heart的数据显示,HF白人患者和亚洲患者在射血分数(EF)与QRS持续时间之间具有不同的关系。亚洲HF患者与白人患者相比,QRS间期延长和EF下降之间的关系更陡峭,不过死亡或HF住院风险没有差异。Crystel M. Gijsberts博士和同事20073名白人HF患者和1084名亚洲HF患者进行了研究,比较QRS持续时间与EF之间的关系差异。荷兰心脏研究所的Gijsberts写道,

CHC 2016:专家建议│心衰合并心律失常的临床治疗

2016年8月11-14日,由中华医学会与国家心血管病中心共同主办的2016年中国心脏大会(CHC 2016)在北京国家会议中心隆重召开,梅斯医学作为特约媒体参与了此次盛会。   来自吉林大学第二医院心血管病医院 刘斌教授做了题为“心衰合并心律失常的临床治疗”的精彩报告。对此,梅斯医学小编进行了整理,与大家分享。心力衰竭及心律失常常常同时存在,相互影响,相互恶化。心力衰竭患

心衰治疗的未来:开阔视野,换个思路

心力衰竭是各种心脏病共同的最后通路,是临床的一个棘手问题。未来,心衰的治疗措施可能会在哪些方面有突破?来自美国塔夫茨医学中心的James E.Udelson 教授带我们换个思路,展开更广阔的心衰治疗视野。 EF 降低心衰:需要换个思路和方向 目前心力衰竭的治疗中,肾素血管紧张素系统抑制剂ACE-I/ARB 是主要手段之一。ATMOSPHERE 研究探索,在ACE-I 基础上加用